Contrary to these findings, Harel et al. examined baseline and on-treatment plasma proteomic profiles of 143 ICI-treated NSCLC patients and found that non-responders had higher levels of plasma CXCL8 and CXCL10 at baseline and on-treatment compared to responders [155]. This evidence concerns the gene CXCL10 and non-small cell lung carcinoma.